Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses (2020 - 2025)

Foghorn Therapeutics has reported Change in Accured Expenses over the past 6 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $1.4 million for Q4 2025, up 159.27% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (up 490.78% YoY), and the annual figure for FY2025 was $2.2 million, up 490.78%.
  • Change in Accured Expenses for Q4 2025 was $1.4 million at Foghorn Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for FHTX hit a ceiling of $5.0 million in Q3 2024 and a floor of -$2.8 million in Q1 2024.
  • Median Change in Accured Expenses over the past 5 years was $792000.0 (2022), compared with a mean of $196850.0.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 15247.06% in 2021 and later soared 764.14% in 2025.
  • Foghorn Therapeutics' Change in Accured Expenses stood at $2.4 million in 2021, then crashed by 62.75% to $894000.0 in 2022, then plummeted by 62.86% to $332000.0 in 2023, then tumbled by 829.22% to -$2.4 million in 2024, then skyrocketed by 159.27% to $1.4 million in 2025.
  • The last three reported values for Change in Accured Expenses were $1.4 million (Q4 2025), $1.2 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.